TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

TCRX AH:

Bid $2.31
Ask $2.33

AH High $2.39

[FACT-MASTER]

TCRX - This will make Baker Bros Advisors LP the largest Institutional holder

https://www.nasdaq.com/market-activity/stocks/tcrx/institutional-holdings

[FACT-MASTER]

TCRX = Institutions adding

https://ih.advfn.com/stock-market/NASDAQ/tscan-therapeutics-TCRX/stock-news/88097459/statement-of-changes-in-beneficial-ownership-4

https://ih.advfn.com/stock-market/NASDAQ/tscan-therapeutics-TCRX/stock-news/88097506/amended-statement-of-beneficial-ownership-sc-13d-a

Baker Bros Advisors LP - TCRX

[FACT-MASTER]

https://ca.finance.yahoo.com/news/tscan-therapeutics-host-virtual-kol-110000808.html

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will host a virtual key opinion leader (KOL) event, to discuss highlights from its presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting as well as its solid tumor program on Thursday, May 19, 2022, at 4:30 p.m. ET.

The event will provide an in-depth review of the oral and poster presentations related to solid tumor TCR-T therapy candidates, TSC-200-A02 for HPV16, and TSC-204-C07 for MAGE-A1, as well as TScan’s approach to potentially overcome antigen heterogeneity and HLA loss with multiplexed TCR-T. Following the prepared remarks, the call will be opened for a live question and answer session. To submit a question, please reach out to [e-mail].

Featured speakers include:

Kai Wucherpfennig, M.D., Ph.D. Chair, Cancer Immunology and Virology and Director, Center for Cancer Immunology Research at the Dana-Farber Cancer Institute, Professor of Neurology, Brigham and Women’s Hospital and Harvard Medical School, and Associate Member, Broad Institute of MIT and Harvard

David Southwell, President and Chief Executive Officer, TScan Therapeutics

Gavin MacBeath, Ph.D., Chief Scientific Officer, TScan Therapeutics

Shrikanta Chattopadhyay, M.D., M.M.Sc., Vice President of Medical, TScan Therapeutics

Registration for the live event can be found here. A replay will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com.

[FACT-MASTER]

https://ca.finance.yahoo.com/news/tscan-therapeutics-reports-first-quarter-110000189.html

[FACT-MASTER]

I lean to the theory that the TCR-T technology ( although much more research is needed) is a better approach to engaging those intrinsic factors of cancer cells where other therapies such as CAR-T , chemo, etc have only limited capabilities. With the abilities of TargetScan, ReceptorScan and T-Integrate, TCRX may have an ability to deliver the best TCR's, and hopefully with duration.

This should be an interesting trial.

I see your point here:

Personally, I hope TCRX test in a similar patient population. Based on the additional transgenes, should lead to an improved depth and duration of response (assuming dose levels in the same range).

Thank you for the added information.

[jondoeuk]

Thanks. I agree. Last year, they identified over 110 novel solid tumour targets in samples from patients who responded to different types of immunotherapy, such as TIL. Taken together with them covering the most common HLAs, they could end up with the largest library of TCRs in the space.

[jondoeuk]

In that trial (US NCI, CRADA with GILD), twelve patients with metastatic HPV-16+ carcinomas were treated. They had 3-7 prior therapies, eight refractory to an anti-PD-1. It was safe ((S)AEs due to LD chemo and high-dose IL-2) and there were six objective responses across all three dose levels tested (likely due to the high levels given).

Personally, I hope TCRX test in a similar patient population. Based on the additional transgenes, should lead to an improved depth and duration of response (assuming dose levels in the same range).

However, none of the responses are ongoing (from memory, the longest was ~14 months). This due to a number of cancer cell intrinsic factors, mostly related to antigen processing and presentation, as well as T-cell recognition and killing.

[FACT-MASTER]

2020 TCRX Press Release regarding collaboration with Novartis:

https://ir.tscan.com/news-releases/news-release-details/tscan-announces-collaboration-novartis-discovery-and-development

Article today regarding Novartis seeking acquisitions:

https://www.fool.com/investing/2022/05/02/novartis-is-looking-for-deals-are-these-3-biotechs/

TCRX market cap is small and is not a candidate according to the above article, however the technology is impressive and imo, has much to offer.

[FACT-MASTER]

cont'd Webcast Details

TScan will host a webcast Thursday, May 19, 2022, at 4:30 p.m. ET. The event will provide a summary of the ASGCT posters and oral presentation as well as a discussion of TScan’s solid tumor programs. The featured speaker will be Kai Wucherpfennig, M.D., Ph.D., Chair, Cancer Immunology and Virology and Director, Center for Cancer Immunology Research at the Dana-Farber Cancer Institute, Professor of Neurology, Brigham and Women’s Hospital and Harvard Medical School, and Associate Member, Broad Institute of MIT and Harvard. The presentation will be followed by a question-and-answer session.

The live audio webcast and accompanying slides may be accessed through the Events and Presentations page in the Investors section of the Company’s website at www.tscan.com. Registration for the event is available here. For those unable to participate in the live webcast, a replay will be available on the Investor section of the Company’s website at https://ir.tscan.com/news/events-and-presentations.

[FACT-MASTER]

https://www.globenewswire.com/news-release/2022/05/02/2434043/0/en/TScan-Therapeutics-Announces-Upcoming-Presentations-at-the-25th-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html

"Summary: Human papilloma virus (HPV)16 E7 oncoprotein is homogenously expressed in every tumor cell of HPV16 positive tumors, is essential for tumor cell survival, and is not expressed by healthy tissues. Using TScan’s proprietary ReceptorScan platform, the Company identified a lead TCR. The lead TCR showed comparable preclinical activity to a therapeutic TCR from NCI, that has previously shown a 50% objective response rate in a Phase I clinical trial. No allo-reactivity was observed for the HLAs tested and only a few putative off-targets were identified using our genome-wide SafetyScan platform. The lead TCR showed no reactivity to primary healthy tissues expressing these putative off-targets during in vitro co-culture experiments indicating minimal off-tumor reactivity risk. To further enhance the function of the therapeutic T cell product, TScan is designing a transposon-based vector that can deliver the TCR gene, along with the genes for CD8a/ß and dominant-negative form of TGFßRII, into both CD4+ and CD8+ T cells. The resulting TCR-T cell therapy candidate, TSC-200-A02, is expected to complete IND-enabling studies in the second half of 2022. These results validate the use of ReceptorScan and SafetyScan as a way to rapidly identify naturally occurring, high affinity TCRs suitable for clinical development."

[FACT-MASTER]

Thank you for posting all the good information.

TScan holds promising technology, and appears to be well managed as well, imo.

[jondoeuk]

The company will host a webcast on Thurs, May 19, at 4:30 p.m. ET. The event will provide a summary of the ASGCT posters and oral presentation as well as a discussion of the solid tumour programs. The featured speaker will be Kai Wucherpfennig, M.D., Ph.D., Chair, Cancer Immunology and Virology and Director, Center for Cancer Immunology Research at the Dana-Farber Cancer Institute, Professor of Neurology, Brigham and Women’s Hospital and Harvard Medical School, and Associate Member, Broad Institute of MIT and Harvard. The presentation will be followed by a question-and-answer session.

[jondoeuk]

852: Discovery of a Novel C07:02-Resticted Epitope on MAGE-A1 and Pre-Clinical Development of an Enhanced TCR-T Cell Therapy Candidate for the Treatment of Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1772

1095: Multiplexed TCR-T Cell Therapy: A Strategy to Enhance the Efficacy of Engineered T Cell Therapy https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1995

317: Discovery of TSC-200-A02: A Natural HPV16 E7-Specific TCR-T Cell Therapy Candidate for the Treatment of HPV-Positive Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1271

[jondoeuk]

ASGCT titles:

Discovery of a Novel C07:02-Resticted Epitope on MAGE-A1 and Pre-Clinical Development of an Enhanced TCR-T Cell Therapy Candidate for the Treatment of Solid Tumors.

Multiplexed TCR-T Cell Therapy: A Strategy to Enhance the Efficacy of Engineered T Cell Therapy.

Discovery of TSC-200-A02: A Natural HPV16 E7-Specific TCR-T Cell Therapy Candidate for the Treatment of HPV-Positive Solid Tumors.

[FACT-MASTER]

https://twitter.com/hashtag/TScanTherapeutics?src=hashtag_click

[FACT-MASTER]

cont'd (link to the study)

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

• ~90% of shared epitopes are not located in the spike protein

https://www.cell.com/immunity/fulltext/S1074-7613(20)30447-7

[FACT-MASTER]

TCRX - Modulating T cells against Covid 19 sure makes more sense then using a mRNA spike vaccine that your T cells can't even recognize.

No wonder the Pfizer and Moderna vaccines don't work, imo.

https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-announces-publication-study-immunity

"WALTHAM, Mass.–(BUSINESS WIRE)–TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies in oncology, today announced the publication of a study identifying the targets of T cells in recovering COVID-19 patients in Immunity, a Cell Press journal. The Company used their target discovery platform, T-Scan, to identify the precise epitope targets in the novel coronavirus that are recognized by the T cells of convalescent patients. The Company found that T cells typically recognize between three and eight targets in coronavirus that are shared among patients with the same human leukocyte antigen (HLA) type. Most of these targets were not located in the Spike protein, a concerning finding as current vaccine development efforts are focused on eliciting an antibody response to the Spike protein. These findings highlight the potential need for second-generation vaccines that incorporate these targets given T cells play an important role in mediating long-term immunity to the virus, as well as the development of T-cell based diagnostics and T cell therapies. The TScan study also showed that patients’ T cells do not cross-react with seasonal coronaviruses that cause the common cold, decreasing the likelihood that prior exposure to these viruses confers immunity to COVID-19.

“T cells play a critical role in fighting viral infections and are particularly important in generating long-term immunity to future infections,” said Gavin MacBeath, Ph.D., Chief Scientific Officer at TScan. “By determining exactly how T cells recognize the novel coronavirus in recovering patients, we can now design second-generation vaccines that elicit a more natural T cell response to the virus than vaccine candidates currently in development. The discovery that antibodies against the virus tend to diminish rapidly in recovering patients underscores the need for new approaches to support the fight against this pandemic.”

“These data highlight the power of our high-throughput T-Scan target discovery platform to quickly identify T cell targets in areas of urgent medical need like COVID-19, and reinforce our belief in the impact this approach can have in our core focus of treating cancer,” said David Southwell, Chief Executive Officer at TScan. “We are actively continuing conversations with partners interested in harnessing the power of our novel discoveries for use in next-generation vaccines, T cell-based diagnostics, and T cell therapeutics for COVID-19.”
TScan’s COVID-19 study was conducted in collaboration with academic partners Atlantic Health System in Morristown, NJ and Ochsner Medical Center in New Orleans, LA that supported the collection of samples from convalescent COVID-19 patients for use in the T-Scan platform. In total, 78 patients were enrolled in this study and all T cell epitopes identified were validated using independent functional assays."

[FACT-MASTER]

TCRX - Dec.31/21 financials cash/cash eq.= $161.4M

https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-reports-full-year-2021-financial-results-and

"Strong balance sheet with cash and cash equivalents of $161.4 million as of December 31, 2021; funds Company into 2024."

[FACT-MASTER]

Top 6 Institutional holders TCRX

BLACKROCK INC. 12/31/2021 1,498,538 -2,039 -0.136% $3,746
BAKER BROS. ADVISORS LP 12/31/2021 1,425,000 0 0% $3,563
HHLR ADVISORS, LTD. 12/31/2021 1,282,976 0 0% $3,207
RA CAPITAL MANAGEMENT, L.P. 12/31/2021 1,255,317 0 0% $3,138
DEER IX & CO. LTD. 09/30/2021 1,245,505 1,245,505 New $3,114
DEER MANAGEMENT CO. LLC 12/31/2021 1,245,505 1,245,505New $3,114


https://www.nasdaq.com/market-activity/stocks/tcrx/institutional-holdings

[FACT-MASTER]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391541/

[FACT-MASTER]

https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01115-0

"It is essential to conquer the obstacles associated with the manufacturing and administration of TCR therapy, including those challenges posed by the immunosuppressive microenvironment in solid tumors, as well as to develop next-generation strategies designed to improve the efficacy and safety of TCR therapies [107]. Although current TCR therapies have the potential to cure selected patients who meet the criteria to receive these treatments, given that MHC-I is downregulated/deficient in 40–90% of patients, these treatments may not be suitable or efficacious for the majority of patients with solid tumors. TCRs are promising because there are more cancer antigens available inside the cells than on the surface, e.g., CAR-T cells can only target surface antigens, whereas engineered TCR-T cells will recognize and attack intracellular tumor-related antigens. These two approaches complement each other. Ongoing and future clinical trials will determine the role of TCR therapy in the armamentarium of therapeutic strategies against cancer.

Conclusion

TCR-based adoptive cell therapies are currently being tested in a variety of advanced cancers with the results to date indicating that the technology is presumptively safe and prospectively efficacious. Such therapies will likely complement, not replace CAR-T-based therapies as their distinct attributes will further address unique aspects associated with the diverse solid tumor landscape. Many challenges need to be addressed to fully exploit TCR-based therapies, including those associated with TCR product manufacturing, patient selection, patient preparation with lymphodepletion, administration of treatment and monitoring of adverse events. Overcoming these challenges, and those posed by the immunosuppressive tumor microenvironment, as well as developing next-generation strategies are essential for improving the efficacy, safety and widespread applicability of TCR-based therapies. Ongoing and future clinical trials will determine the role of TCR therapy in patients with solid tumors."

[FACT-MASTER]

https://www.tscan.com

Interesting approach to cancer therapy.

[jondoeuk]

Slides https://ir.tscan.com/static-files/f3ba2ecc-f7bb-4bc9-b3ff-11b8ad44de71

[jondoeuk]

ASH PR https://www.globenewswire.com/news-release/2021/12/13/2350890/0/en/TScan-Therapeutics-Announces-Poster-Presentations-at-the-63rd-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html

Posters https://www.tscan.com/wp-content/uploads/2021/12/Chattopadhyay-et-al.-Product-Characteristics-and-Multi-Arm-Clinical-Trial-Design-for-TSC-100-and-TSC-101-TCR-T-Cells-That-Target-Leukemia-Following-Hematopoietic-Cell-Transplantation.-ASH-2021.pdf https://www.tscan.com/wp-content/uploads/2021/12/Nayar-R.-et-al.-Discovery-of-TSC-101-A-First-in-Class-Natural-HA-2-Specific-TCR-to-Treat-Leukemia-Following-Hematopoietic-Stem-Cell-Transplant-Therapy.-ASH-2021.pdf

[jondoeuk]

Upcoming (ASH) event on Dec 15, at 4:30 PM EST

Link to webcast https://kvgo.com/corporate-services/tscan-therapeutics-ash-update-call

[jondoeuk]

ASH abstracts

Product Characteristics and Multi-Arm Clinical Trial Design for TSC-100 and TSC-101, TCR-T Cells That Target Leukemia Following Hematopoietic Cell Transplantation https://ash.confex.com/ash/2021/webprogram/Paper153844.html

Discovery of TSC-101: A First-in-Class Natural HA-2-Specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy https://ash.confex.com/ash/2021/webprogram/Paper151317.html

[crudeoil24]

Recent IPO > Tscan Therapeutics Inc is a United States-based preclinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. TScan is engaged in advancing a pipeline of TCR-T therapy candidates for the treatment of patients with hematologic and solid tumor malignancies. Its lead liquid tumor product candidates, TSC-100 and TSC-101, are under development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. The Company's solid tumor TCR-T therapy candidates include a combination of known targets, such as HPV16 for TSC-200 and Preferentially Expressed Antigen in Melanoma (PRAME) for TSC-203. The Company's platform technologies include TargetScan, ReceptorScan and T-Integrate.